Additionally, lactylation of IGF2BP3 enhances S-adenosylmethionine (SAM) synthesis and RNA m6A modification, fostering therapeutic resistance, particularly lenvatinib resistance in HCC (111). This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.